By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now moves to the next layer of the De-Risk Stack. In the previous article, technical risk addressed whether a product works and can be trusted. The next question is whether it can realistically be approved.
This article examines regulatory risk, where feasibility must become predictability. It outlines how companies define a clear path to approval—covering regulatory pathways, precedent, endpoint selection, trial design, and engagement with regulators.
From aligning with evidence requirements to understanding timelines and cost, this piece breaks down what it takes to move from promising data to an executable plan that investors can underwrite.
Regulatory Risk
From Feasibility to Predictability
Once the product works, the next question is whether it can be approved.
Regulatory risk is often underestimated because it is treated as an after-the-fact compliance requirement instead of a primary design constraint. In reality, it defines timelines, capital requirements, and feasibility. Without a credible path, investment becomes difficult regardless of how strong the data may be.
The core issue is predictability. Investors need to understand not just that approval is possible, but how it will be achieved, how long it will take, and what it will cost.
This begins with pathway clarity. The regulatory route must be defined early—whether the asset is headed toward an IND and NDA/BLA, a 510(k), a PMA, or another pathway. Precedent provides context by showing how similar products, mechanisms, or indications have been evaluated. Without precedent, uncertainty and perceived risk rise sharply.
Endpoints and trial design then determine whether the plan is executable. Success must be measurable in a way regulators accept, and the required studies must be feasible in terms of recruitment, duration, complexity, and cost. A theoretically elegant trial that cannot be run in the real world is equivalent to having no trial plan at all.
Regulatory interaction further refines the path. Pre-IND or pre-submission meetings align expectations, clarify requirements, and reduce unnecessary iteration. Proceeding without this engagement increases risk and can lead to expensive rework.
Safety requirements, timeline expectations, and the cost of approval define the remaining boundaries. Each indication and modality carries a different tolerance for risk and a different evidence bar, and each pathway implies a specific capital profile.
Regulatory risk is resolved when the path to approval is defined, evidence requirements are understood, and the plan is both credible and executable within known time and capital constraints.
Core Elements of Regulatory Risk
- Pathway clarity
- Precedent
- Endpoint definition
- Trial design feasibility
- Regulatory interaction
- Safety requirements
- Timeline predictability
- Cost of approval
Next in the series: Execution Risk — Turning Plan into Progress
Previous Articles：
Technical Risk – From Belief to Evidence
The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability
Next Phase Newsletter 
Leave a comment